Full text is available at the source.
Abstract
Improved molecular definition of PEG interfaces may enhance predictability and manufacturing reproducibility in mRNA therapeutics.
- PEG-lipids play a critical role in stabilizing mRNA lipid nanoparticles but can present delivery challenges with repeat dosing.
- Design variables such as chain length, terminal chemistry, and PEG fraction can influence the effectiveness of PEG-lipids.
- Utilizing discrete-molar-mass PEG-lipids and controlling their structure may reduce variability in immune responses.
- Enhanced understanding of interfacial properties, like surface density and dissociation rates, could clarify how PEG-lipids function.
- Interface design strategies, combined with immune-aware dosing, may lead to improved clinical outcomes for mRNA therapeutics.
Simplified